Aurobindo Pharma to launch ₹800 crore buyback at ₹1,475 per share from April 23

Shares of Aurobindo Pharma Ltd ended at ₹1,387.05, down by ₹19.35, or 1.41%, on the BSE.

Aurobindo Pharma Ltd on Tuesday (April 21) said it has submitted the Letter of Offer for its buyback of equity shares worth up to ₹800 crore through the tender offer route.

The buyback covers up to 54.23 lakh fully paid-up equity shares of face value ₹1 each at a price of ₹1,475 per share, payable in cash. The company said the Letter of Offer dated April 21, 2026, has been emailed to eligible shareholders holding shares as on the record date of April 17, 2026.

The buyback will open on April 23, 2026 and close on April 29, 2026. The last date for receipt of completed tender forms and related documents by the registrar is April 29, 2026.

Also Read: Aurobindo Pharma gets FDA nod for cough medicine dextromethorphan ER

Settlement of bids by the clearing corporation/BSE is scheduled for May 7, 2026. The company had earlier submitted the public announcement for the buyback on April 8, 2026.

Buyback History

This is Aurobindo Pharma's first share buyback in nearly two years. Back in August 2024, the company had announced the repurchase of 51.36 lakh equity shares at a price of ₹1,460 apiece. The drugmaker had spent ₹750 crore for this buyback, which was also carried out via the tender offer route.

Shares of Aurobindo Pharma Ltd ended at ₹1,387.05, down by ₹19.35, or 1.41%, on the BSE.

Also Read: Aurobindo Pharma arm expands MSD pact, to invest $150-175 million in new facility

(Edited by : Jomy Jos Pullokaran )